CDC 117

Drug Profile

CDC 117

Alternative Names: Selective estrogen receptor modulators - Celgene

Latest Information Update: 07 May 2007

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 May 2007 Discontinued - Clinical-Phase-Unknown for Cancer in USA (unspecified route)
  • 04 Feb 2002 New profile
  • 04 Feb 2002 Investigation in Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top